Suppr超能文献

主动脉内反搏:C 脉冲和其他心脏支持设备。

Aortic counterpulsation: C-pulse and other devices for cardiac support.

机构信息

Division of Cardiology, Rutgers-New Jersey Medical School, 185 S. Orange Avenue, Newark, NJ, 07103, USA,

出版信息

J Cardiovasc Transl Res. 2014 Apr;7(3):292-300. doi: 10.1007/s12265-014-9548-6. Epub 2014 Feb 20.

Abstract

Heart failure is the leading cause of hospitalization in the USA. Despite major advances in the medical and device-related therapy including chronic resynchronization therapy for management of heart failure, significant number of patients eventually require advanced cardiac therapy including mechanical circulatory support or heart transplant. Heart transplant is a gold standard for end-stage heart failure but is limited by the donor heart shortage creating a definite need for alternative effective therapies. The earliest and most common form of mechanical circulatory support is counterpulsation therapy. Annually, more than 150,000 patients worldwide receive counterpulsation therapy for various indications including cardiogenic shock or severe left ventricular dysfunction (Nanas and Moulopoulos in Cardiology, 84:156-167, 1994) and many thousands of lives are saved each year (65 % survival) (Torchiana et al. in Journal of Thoracic and Cardiovascular Surgery, 113(4):758-764, 1997). There are different types of aortic counterpulsation devices. Here, we will give an overview of different counterpulsation devices with focus on C-Pulse device. Extra-aortic balloon counterpulsation, C-Pulse (Sunshine Heart Inc., Eden Prairie, MN), is an important and novel approach in the management of patients with advanced heart failure who remain symptomatic despite optimum medical and device-based therapy. C-Pulse is designed to provide permanent, long-term, continuous partial circulatory support for New York Heart Association class III and ambulatory class IV heart failure patients. C-Pulse is a nonblood-contacting counterpulsation using an inflatable cuff around the ascending aorta, extra-aortic balloon (EAB) counterpulsation device. A pivotal, multicenter US study to assess the safety and efficacy of C- Pulse in patient with Stage C and NYHA Class III or ambulatory Class IV heart failure is in progress.

摘要

心力衰竭是美国住院的主要原因。尽管在医学和器械相关治疗方面取得了重大进展,包括慢性心脏再同步化治疗心力衰竭的管理,但仍有相当数量的患者最终需要先进的心脏治疗,包括机械循环支持或心脏移植。心脏移植是心力衰竭终末期的金标准,但由于供心短缺,确实需要替代有效的治疗方法。最早和最常见的机械循环支持形式是反搏治疗。全球每年有超过 150,000 名患者因各种适应症接受反搏治疗,包括心源性休克或严重左心室功能障碍(Nanas 和 Moulopoulos 在 Cardiology, 84:156-167, 1994),每年挽救了数千人的生命(65%的生存率)(Torchiana 等人在 Journal of Thoracic and Cardiovascular Surgery, 113(4):758-764, 1997)。有不同类型的主动脉反搏装置。在这里,我们将概述不同的反搏装置,重点介绍 C-Pulse 装置。体外气囊反搏,C-Pulse(阳光之心公司,明尼苏达州伊登草原),是一种重要而新颖的方法,用于管理尽管接受了最佳的药物和器械治疗仍有症状的晚期心力衰竭患者。C-Pulse 旨在为纽约心脏协会 III 级和非卧床 IV 级心力衰竭患者提供永久性、长期、连续的部分循环支持。C-Pulse 是一种非接触式反搏,使用围绕升主动脉的可充气袖带和体外气囊(EAB)反搏装置。一项评估 C-Pulse 在 C 期和 NYHA 分级 III 或非卧床分级 IV 心力衰竭患者中的安全性和有效性的多中心美国关键研究正在进行中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验